Stockscreener 앱 받기
2.00
12.66%
-0.29
시간 외 거래:
2.10
0.10
+5.00%
Relay Therapeutics Inc 주식(RLAY)의 최신 뉴스
Raymond James Financial Inc. Invests $779,000 in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace
Cancer drug developer cuts staff for the third time in a year - The Business Journals
Relay Therapeutics Inc (RLAY) Recovers -2.97% From Low: Are We There Yet? - stocksregister.com
Thrivent Financial for Lutherans Grows Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Teacher Retirement System of Texas Purchases 5,492 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics stock hits 52-week low at $2.44 - Investing.com India
Relay Therapeutics stock hits 52-week low at $2.44 By Investing.com - Investing.com UK
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by Virtu Financial LLC - Defense World
Relay Therapeutics’ SWOT analysis: promising drug data boosts stock outlook - Investing.com
Relay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines! - Insider Monkey
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Purchased by HighTower Advisors LLC - Defense World
Charles Schwab Investment Management Inc. Decreases Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Relay Therapeutics stock hits 52-week low at $3.01 amid market challenges By Investing.com - Investing.com South Africa
Relay Therapeutics stock hits 52-week low at $3.01 amid market challenges - Investing.com India
Bank of New York Mellon Corp Buys 50,190 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Investor Alert: What’s Really Going On At Relay Therapeutics Inc (NASDAQ: RLAY) - Stocks Register
Victory Capital Management Inc. Has $63,000 Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Steward Partners Investment Advisory LLC Purchases 4,000 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Head-To-Head Contrast: Relay Therapeutics (NASDAQ:RLAY) & Kyverna Therapeutics (NASDAQ:KYTX) - Defense World
Relay Therapeutics’ SWOT analysis: promising drug faces stiff competition By Investing.com - Investing.com South Africa
Relay Therapeutics’ SWOT analysis: promising drug faces stiff competition - Investing.com India
Arizona State Retirement System Acquires 7,547 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics’ SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Relay Therapeutics’ SWOT analysis: stock poised for growth amid challenges - Investing.com
Relay Therapeutics’ (RLAY) Buy Rating Reiterated at HC Wainwright - Armenian Reporter
HC Wainwright Reiterates “Buy” Rating for Relay Therapeutics (NASDAQ:RLAY) - Defense World
Rhumbline Advisers Acquires 13,532 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
New York State Common Retirement Fund Has $121,000 Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY) - Yahoo Finance
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
The Goldman Sachs Group Lowers Relay Therapeutics (NASDAQ:RLAY) Price Target to $18.00 - Defense World
Stifel Nicolaus Issues Pessimistic Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price - Defense World
Relay Therapeutics (NASDAQ:RLAY) Sets New 1-Year Low After Analyst Downgrade - Defense World
Relay Therapeutics price target lowered to $12 from $21 at Citizens JMP - TipRanks
Relay Therapeutics stock target cut to $12 at Citizens JMP - Investing.com
Buy Rating for Relay Therapeutics Driven by Strategic Advancements and Promising Clinical Trial Developments - TipRanks
RLAY stock touches 52-week low at $3.34 amid market challenges - Investing.com
Relay Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Relay Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Relay Therapeutics reports Q4 EPS (45c), consensus (55c) - TipRanks
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates - The Manila Times
Relay Therapeutics, Inc. SEC 10-K Report - TradingView
3.01%
자본화:
|
볼륨(24시간):